ArticleFrontiers in bioinformatics2026
An integrative machine learning, explainable AI, molecular simulation, and cytotoxicity validation framework for the discovery of selective SIRT1 inhibitors against triple negative breast cancer.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple negative breast cancer (TNBC) is an aggressive disease characterized by a poor prognosis, high decline rates, lack of hormonal receptors for targeted therapy, limited effectiveness of existing treatments, and the emergence of chemoresistance. Sirtuin1 (SIRT1) is an epigenetic modifier and nicotinamide adenine dinucleotide (NAD+) dependent class III histone deacetylase (HDACs) protein. It promotes the modulation of several tumour suppressors and oncogenes. The evidence also suggests that inhibiting SIRT1 activity using selective SIRT1 inhibitors could restore E-cadherin expression and suppress EMT-mediated metastasis in TNBC cells. Though we have many SIRT1 protein inhibitors, they exhibited off-target effects, low isoform selectivity, and inefficiency at the clinical trial stage. Methods: In this study, we aim to identify SIRT1 isoform inhibitors by utilizing an integrated computational approach. Three stages of ML modelling were performed to find the best model from the SIRT1-based dataset. The QDA + ROS and XGBClassifier + ROS models were identified as the most robust, and they were subjected to the SHAP framework (XAI approach) to address the "black box" nature of the developed ML models. The NPASS natural compound dataset was first screened with the applicability domain of the developed models, followed by a two-step virtual screening with UniDock and AutoDock GPU in Scientiflow. Finally, the selected compounds were taken for molecular dynamics simulation, with rigorous trajectory analysis, and preliminary experimental validation was done. Results: The compounds with NPASS IDs: NPC216682, NPC480509, NPC210910, and NPC247082 were identified as the most promising hits. Among these hits, Praziquantel (NPC480509), the only available test compound with reported anticancer properties, revealed the cytotoxic nature on MDA-MD-231 and MCF7 breast cancer cell lines, whereas non-cytotoxic on normal breast cell line (MCF10A). Conclusion: This study is exploratory. Exact SIRT1 selective inhibition by Praziquantel, along with other hits, may be further studies thorugh
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.